parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in myonuclei	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	15 Parkinson's papers of 890	0.64
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 6714

receipt 6722: FOXP2 in dopamine neurons, braak

power: full sample +0.33 (p 0.179, n 18), 95% CI -0.16 to +0.69. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.29 (p 0.250, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.351, n 18). could be the mix.
skeptic: leave-one-out range +0.23 to +0.52, sign flips 0; without severely affected donors +0.33 (p 0.179, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FOXP2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6721: FOXP2 in microglia, braak

power: full sample +0.01 (p 0.962, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.00 (p 0.990, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.02 (p 0.928, n 18). could be the mix.
skeptic: leave-one-out range -0.09 to +0.17, sign flips 7; without severely affected donors +0.01 (p 0.962, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FOXP2 in microglia.

case closed: nothing better to follow up.

loading the receipts